2024
SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL
PEŠL, Martin; Daniil KABANOV; Šimon VRANA; Deborah BECKEROVÁ; Martin MOLČAN et al.Základní údaje
Originální název
SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL
Autoři
PEŠL, Martin; Daniil KABANOV; Šimon VRANA; Deborah BECKEROVÁ; Martin MOLČAN; Martin ŠČUREK; Kristián BRAT; Markéta BÉBAROVÁ ORCID; Vladimír ROTREKL; Jan PŘIBYL ORCID a Zdeněk STÁREK
Vydání
Czech Cardiovascular Research and Innovation Days 2024. 2024
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/24:00137446
Organizační jednotka
Lékařská fakulta
Klíčová slova anglicky
Salbutamol; Aminophylline; Atomic force microscopy; iPSC; HESC; Cardiomyocytes; Pulmonary drug screening; Drug cardiotoxicity; Biomechanical properties; Arrhythmogenic effects
Změněno: 19. 12. 2025 12:49, Mgr. Petra Trembecká, Ph.D.
Anotace
V originále
Background: The combination of aminophylline and salbutamol is used in the treatment of obstructive lung diseases. Side effects (including arrhythmias) of the individual bronchodilator drugs were described, those of combined treatment are almost unknown. We aimed to study the arrhythmogenic potential of combined aminophylline and salbutamol in vitro. Methods: We used the established model of atomic force microscopy (AFM) coupled with cardiac organoids from human pluripotent stem cells (hPSC-CMs). We focused on the chronotropic, inotropic, and arrhythmogenic effects of Salbutamol and Aminophylline alone and combined. Results: Salbutamol and Aminophylline had a synergistic chronotropic and inotropic effects compared to the effects of their separate application. Salbutamol reduced the arrhythmogenic effect of aminophylline, most likely mediated by endothelial nitric oxide synthase activated by beta-2 adrenergic receptors. Findings were replicated and confirmed using hPSC-CM derived from 2 cell lines (CCTL14 and CCTL12). Conclusions: Data suggest that salbutamol as an add-on therapy may not only deliver a bronchodilator effect but also increase the cardiovascular safety of aminophylline, as salbutamol reduces its arrhythmogenic potential. Acknowledgement CarDia (EXCELES, No. LX22NPO5104) EU Next Generation and by the EC Horizon Europe MUQUABIS GA no. 101070546. and MUNI/A/1624/2023 MEYS CR
Návaznosti
| LM2023069, projekt VaV |
| ||
| MUNI/A/1624/2023, interní kód MU |
| ||
| NU20-06-00156, projekt VaV |
|